![Human Interleukin-11 (Highly Pure)](/proxy_img/aHR0cHM6Ly9tb2xlY3VsYXJkZXBvdC5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMjEvMDEvQjIwMTAyODYucG5n.png)
![All Products](/proxy_img/aHR0cHM6Ly9tb2xlY3VsYXJkZXBvdC5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMTkvMDUvQWxsUHJvZHVjdHMtNjAweDUwOS5wbmc=.png)
Human Interleukin-11 (Highly Pure)
Catalog Number: B2010286 (10 ug)
Human Interleukin-11 (Highly Pure) is a high quality research product used as highly pure Human Interleukin-11 expressed in CHO cells. This protein acts as a protein with protective roles. It also accelerates the recovery of platelets and lessen the extent of inflammatory responses. Custom bulk orders of this product are available upon request.
Product Description
Human Interleukin-11 (Highly Pure)
Catalog number: B2010286
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure Human Interleukin-11 (Highly Pure) expressed in CHO cells. This protein acts as a protein with protective roles. It also accelerates the recovery of platelets and lessen the extent of inflammatory responses.
Storage: -20C
Keywords: rHuIL-11; Adipogenesis inhibitory factor; AGIF
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
References:
1: Gomes IA, de Carvalho FO, de Menezes AF, Almeida FM, Shanmugam S, de Souza
Siqueira Quintans J, Quintans-Júnior LJ, de Moura TR, Oliveira PD, de Souza
Araújo AA. The role of interleukins in vitiligo: a systematic review. J Eur Acad
Dermatol Venereol. 2018 Dec;32(12):2097-2111.
2: Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for
new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153.
3: Elmslie RE, Dow SW, Ogilvie GK. Interleukins: biological properties and
therapeutic potential. J Vet Intern Med. 1991 Sep-Oct;5(5):283-93.
4: Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1
cytokine family–Balance between agonists and antagonists in inflammatory
diseases. Cytokine. 2015 Nov;76(1):25-37.
5: Chen J, Ma A. Associations of polymorphisms in interleukins with
tuberculosis: Evidence from a meta-analysis. Immunol Lett. 2020 Jan;217:1-6.
6: Rozycki HJ, Zhao W. Interleukins for the paediatric pulmonologist. Paediatr
Respir Rev. 2014 Mar;15(1):56-68.
7: Quesniaux VF. Interleukins 9, 10, 11 and 12 and kit ligand: a brief overview.
Res Immunol. 1992 May;143(4):385-400.
8: Herrod HG. Interleukins in immunologic and allergic diseases. Ann Allergy.
1989 Oct;63(4):269-72.
9: Akiyama M. Regarding “Upregulated interleukins (IL-6, IL-10, and IL-13) in
immunoglobulin G4-related aortic aneurysm patients”. J Vasc Surg. 2017
Dec;66(6):1919.
10: Candel-Martí ME, Flichy-Fernández AJ, Alegre-Domingo T, Ata-Ali J,
Peñarrocha-Diago MA. Interleukins IL-6, IL-8, IL-10, IL-12 and periimplant
disease. An update. Med Oral Patol Oral Cir Bucal. 2011 Jul 1;16(4):e518-21.
11: Behzadi P, Behzadi E, Ranjbar R. IL-12 Family Cytokines: General
Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways.
Acta Microbiol Immunol Hung. 2016 Mar;63(1):1-25.
12: Holcombe RF. Clinical applications of the interleukins: present and future.
J La State Med Soc. 1994 Nov;146(11):479-83.
Products Related to Human Interleukin-11 (Highly Pure) : Proteins
Additional Information
Weight | 0.15 oz |
---|---|
Dimensions | 2 × 0.5 × 0.5 in |